eli lilly ceo on weight loss drugs outlook: our top priority is making more product
Published 4 months ago • 32K plays • Length 6:43Download video MP4
Download video MP3
Similar videos
-
5:33
eli lilly ceo david ricks on 3-year obesity drug study: this is a profound result
-
6:00
eli lilly's zepbound may be best-in-breed for weight loss drugs, says dr. kavita patel
-
4:09
excitement grows around eli lilly's glp-1 drugs in q2 earnings
-
4:13
will eli lilly’s weight-loss drug be a gamechanger? | vantage with palki sharma
-
4:21
eli lilly's weight-loss drug could be the best selling drug of all time, says jim cramer
-
1:46
eli lilly releases new form of weight loss drug zepbound for half the price to boost access, supply
-
0:59
eli lilly ceo on why food companies haven't seen a big impact on sales
-
2:56
eli lilly to offer weight loss drug directly to qualifying customers at lower price
-
6:05
eli lilly ceo david ricks on q2 results: seeing unbelievable demand for zepbound and mounjaro
-
1:32
eli lilly's weight loss drug slashes the risk of developing diabetes in long-term trial
-
7:04
exclusive: how eli lilly’s making weight loss drugs more accessible
-
4:14
eli lilly ceo david ricks on glp-1 and obesity drugs
-
6:29
dr. scott gottlieb on weight loss drugs side effects, eli lilly's direct-to-consumer bet
-
6:08
eli lilly ceo on slashing insulin prices, approval timelines for weight-loss and alzheimer's drugs
-
5:24
eli lilly goes direct-to-consumer on weight loss drugs: what patients and investors need to know
-
5:06
eli lilly and novo can 'coexist for awhile' in the weight-loss drug space, says bmo's evan seigerman
-
4:29
eli lilly ceo david ricks breaks down q1 earnings, obesity drug trial results
-
5:53
eli lilly and novo nordisk will remain leaders in the weight-loss drug market: mizuho's jared holz
-
5:22
eii lilly's weight-loss drug is 'much better' than others on the market, says wells fargo's bansal
-
2:40
eli lilly slashes prices of low doses of weight loss drug by scrapping auto-injector
-
4:35
jim cramer weighs the market impact of eli lilly and novo nordisk's weight loss drugs
-
3:40
eli lilly's obesity drug will be a tailwind for the stock, says bmo's evan seigerman